Company profile
Refeyn Ltd
Refeyn - Measuring molecules with light
Our goal is to make mass photometry available to the scientific community. We specialise in label-free single molecule imaging and mass measurement of biomolecules in solution.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Second Filing Notification Of A Person With Significant Control
Persons-with-significant-controlRP04PSC02 | Transaction MzUxMzUzMDIxMGFkaXF6a2N4 | Paper/PDF filed
Published 01 Apr 2026 22:47
Accounts filed
AccountsLast accounts made up date
Capital Allotment Shares
CapitalSH01 | Transaction MzQ0MzU2MDk2OGFkaXF6a2N4
Published 15 Nov 2024 12:29
Appoint Person Secretary Company With Name Date
OfficersAP03 | Transaction MzQzNjE5OTk3MGFkaXF6a2N4
Published 17 Sep 2024 11:39
Incorporated
InceptionCompany registered at Companies House
Spinout profile
Company description
Refeyn develops technology that is capable of measuring and imaging molecular mass.
Refeyn Ltd is a spin-out from the University of Oxford, that employs ~30 people (most in Oxford, but also in the US and Germany) to develop mass photometry and make it available to the research community.
Project impact
The company is new, but has attracted significant recent investment
Refeyn and sold and delivered instruments to labs around the world, with researchers in academia and industry using the instrumentation to perform new science. The company is revenue generating, and has raised significant amount of venture capital funding, and has created a diverse set of jobs.
Public funding
Projects
Advanced process control of AAV manufacture: digitalisation, PAT and automation to improve productivity, quality and consistency
1 Jun 2023 to 31 May 2025
The therapeutic potential for gene therapies is transformative, where many largely intractable diseases will be treated safely, effectively and durably. Therapies are now starting to get approved (e.g. Roctavian, Zolgensma, and Luxturna), but cost remains a large barrier to entry and widespread patient access, partly due to suboptimal manufacturing proces...
Accelerating analytics for gene therapy using enhanced mass photometry
1 Oct 2020 to 30 Sep 2021
Gene therapy holds huge promise for many conditions that have been difficult to prevent or treat using conventional drugs, including inherited, rare and age-related diseases, and cancers. As the industry grows, there is an urgent need for more efficient, effective technologies for quality control tests. Technologies developed for traditional drugs have ma...